DOJ is ramping up, not ramping down, health care fraud enforcement
By 
Adrianne Appel2025-10-03T21:24:00
While the Trump administration may have shifted away from pursuing small, white-collar, financial crimes, its focus on health care fraud cases is as hot as ever.
Related articles
-
ArticleJudge orders CVS to pay nearly $290M for Medicare false claims
CVS’s Caremark division knowingly overcharged Medicare for prescription drugs and must pay nearly $290 million, a Pennsylvania federal judge has ordered.
-
ArticleNew York lab CEO allegedly billed insurers for $500M in fraudulent COVID test claims
The U.S. Department of Justice says the chief executive and medical director of Fast Lab Technologies allegedly engaged in a $500 million fraud scheme involving COVID-19 tests.
-
News BriefCVS hit with nearly $1 billion fine in Omnicare false claims verdict
CVS has vowed to appeal $948.8 million in fines and damages imposed by a judge Tuesday on its Omnicare unit, for billing Medicare for tens of thousands of false claims.
More from Regulatory Policy
-
ArticleU.K. outlines AI sandbox plan as regulators weigh compliance risks
The U.K. has set out a new blueprint for AI regulation, which aims to slash bureaucracy and ramp up the safe adoption of new and emerging technology to unlock potential and boost investment.
-
ArticleCalifornia may create whistleblower program to root out privacy law violations
A California privacy agency plans to seek a whistleblower law, to encourage corporate employees and others to step forward with complaints about egregious privacy violations at their workplaces.
-
News BriefCFPB proposes changes to equal credit opportunity act rules
The U.S. Consumer Financial Protection Bureau (CFPB) proposed a rule change that would narrow anti-discrimination requirements for the financial industry. This comes as the Trump administration attempts to shutter the agency may finally come to pass.